- Home
- LILAK vs KNSA Comparison
LILAK vs KNSA Comparison
Compare LILAK & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILAK
- KNSA
- Stock Information
- Founded
- LILAK 2017
- KNSA 2015
- Country
- LILAK Bermuda
- KNSA United Kingdom
- Employees
- LILAK N/A
- KNSA N/A
- Industry
- LILAK Cable & Other Pay Television Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- LILAK Telecommunications
- KNSA Health Care
- Exchange
- LILAK Nasdaq
- KNSA Nasdaq
- Market Cap
- LILAK 1.4B
- KNSA 1.6B
- IPO Year
- LILAK N/A
- KNSA 2018
- Fundamental
- Price
- LILAK $6.33
- KNSA $23.09
- Analyst Decision
- LILAK Buy
- KNSA Strong Buy
- Analyst Count
- LILAK 3
- KNSA 6
- Target Price
- LILAK $10.27
- KNSA $37.17
- AVG Volume (30 Days)
- LILAK 786.4K
- KNSA 634.6K
- Earning Date
- LILAK 05-06-2025
- KNSA 04-22-2025
- Dividend Yield
- LILAK N/A
- KNSA N/A
- EPS Growth
- LILAK N/A
- KNSA N/A
- EPS
- LILAK N/A
- KNSA N/A
- Revenue
- LILAK $4,456,900,000.00
- KNSA $423,239,000.00
- Revenue This Year
- LILAK $3.68
- KNSA $37.21
- Revenue Next Year
- LILAK $3.55
- KNSA $1.38
- P/E Ratio
- LILAK N/A
- KNSA N/A
- Revenue Growth
- LILAK N/A
- KNSA 56.60
- 52 Week Low
- LILAK $5.88
- KNSA $16.56
- 52 Week High
- LILAK $10.93
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- LILAK 40.44
- KNSA 60.12
- Support Level
- LILAK $6.44
- KNSA $22.62
- Resistance Level
- LILAK $6.80
- KNSA $23.42
- Average True Range (ATR)
- LILAK 0.23
- KNSA 0.75
- MACD
- LILAK -0.03
- KNSA -0.01
- Stochastic Oscillator
- LILAK 2.82
- KNSA 68.88
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico, and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.